ATOS

Atossa Genetics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hormone-driven oncology and rare diseases. The company specializes in next-generation selective estrogen receptor modulators and degraders, particularly (Z)-endoxifen, to address unmet medical needs in conditions such as breast cancer and rare diseases like McCune-Albright Syndrome and Duchenne Muscular Dystrophy. Atossa operates a clinical research platform aimed at improving patient care and expanding treatment options for hormone-driven conditions.